NASDAQ$GYRE
Gyre Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Revenue and net profit increased compared to the same period last year.
Beijing Continent Pharmaceuticals Co., Ltd. reported an increase in revenue and net profit for the six months ended June 30, 2023. Revenue increased to RMB 379,265 thousands from RMB 312,673 thousands. Net profit increased to RMB 81,198 thousands from RMB 63,876 thousands.
- Revenue from sales of pharmaceutical products reached RMB 379,265 thousands.
- Net profit was RMB 81,198 thousands.
- The company was approved as a High and New Technology Enterprise, entitling it to a preferential tax rate of 15%.
- Shareholders approved to terminate the 2021 Stock Incentive Plan.
Headline financials
Revenue & EPS history
Gyre Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Gyre Therapeutics · $2.3M total across 1 segment · Q3 2021
- License & Collaboration$2.3M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+11.6%
Q3 2018
Best reaction
-43.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.8% | +2.8% | -11.2% | |
| Q4 2025 | +2.0% | -10.2% | -5.4% | |
| Q3 2025 | -1.6% | +13.6% | +8.7% | |
| Q1 2025 | +0.5% | +9.6% | -11.3% | |
| Q3 2024 | -13.6% | -21.2% | -39.8% | |
| Q2 2024 | -6.5% | +2.1% | +28.7% | |
| Q1 2024 | -5.5% | +0.5% | -29.3% | |
| Q4 2023 | +8.3% | +8.0% | +0.9% | |
| Q3 2023 | +0.0% | -15.3% | +144.2% | |
| Q2 2023 | +8.8% | +58.8% | +50.0% | |
| Q1 2023 | +5.0% | +5.0% | +5.0% | |
| Q4 2022 | +5.0% | +5.0% | +5.0% | |
| Q3 2022 | -1.8% | +0.0% | -12.5% | |
| Q2 2022 | -1.6% | +3.6% | +2.1% | |
| Q1 2022 | -24.5% | -26.5% | +173.5% | |
| Q4 2021 | +0.0% | -3.0% | -27.3% | |
| Q3 2021 | -43.2% | -51.0% | -62.9% | |
| Q2 2021 | +7.4% | +3.7% | +10.3% | |
| Q1 2021 | -2.4% | -5.4% | -9.5% | |
| Q3 2020 | +4.5% | +7.4% | +11.3% | |
| Q2 2020 | -0.6% | -2.0% | -13.5% | |
| Q1 2020 | +7.2% | -2.7% | +21.9% | |
| Q3 2019 | -3.1% | -6.1% | -8.7% | |
| Q2 2019 | +6.7% | -3.2% | -22.1% | |
| Q1 2019 | -5.3% | +2.7% | -9.2% | |
| Q3 2018 | +11.6% | +24.7% | +20.0% | |
| Q2 2018 | +6.6% | +6.6% | +11.9% | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | -5.4% | — | — | |
| Q2 2013 | -3.6% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | -2.7% | — | — | |
| Q1 2012 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2009 | +0.1% | — | — | |
| Q3 2010 | +3.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q4 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro